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have conﬁrmed 383 human cases with a fatality rate of 63%
(241/383) as per WHO May 2008 data. The major share is from
three South East Asian (SEA) countries—Vietnam, Thailand and
Indonesia, which together accounted to 177 deaths from 264
cases. Poultry sector contributes 1.2–2.4% of GDP in East Asian
and paciﬁc countries. Bird ﬂu has encroached poultry trade in
South East Asia killing more than 120 million birds with a gross
economic loss of US$10 billion compared to 300 million birds
killed globally with economic loss of US$20 billion (0.5–1% fall
in GDP) since 2003. The impact extends not only to poultry
farmers but also to upstream and downstream sectors (poultry
trade, breeding farms, tourism etc.). A recent analysis has pro-
jected that a future pandemic could kill 5–150 million people
leading to a 3.1–5.1% loss of world GDP (US$1.2–2 trillion).
CONCLUSIONS: Health and economic losses have posed a
major challenge to South East Asia. Appropriate and timely
measures are required to prevent a future pandemic which could
be devastating to Asia and rest of the world.
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OBJECTIVES: Human Papilloma Virus (HPV) is responsible for
both benign and malignant genital disease. The objective of this
study was to review the available epidemiological and cost in-
formation for genital warts (GW), with a focus on the female
population, the current target for HPV vaccination in Italy.
METHODS: The study analyzed scientiﬁc literature, data from
the Italian Centres of Surveillance of Sexually Transmitted Infec-
tions (MST), the National Hospital Discharge and the National
Drug Utilisation databases. National tariffs for ambulatory visits,
hospitalizations and drugs costs were used to estimate the overall
cost of GW disease for the Italian National Health System
(NHS). The overall cost for prevention and treatment of cervical
cancer was taken from La Torre 2007. RESULTS: No Italian
speciﬁc publications were found regarding GW epidemiology;
however from applying European incidence rates to the female
Italian population, 30,000 new GW cases/year were estimated.
According to MST data, there were 8,000 public clinic visits
relating to female GWs (20,000 visits for male GWs), suggestive
of a considerable use of private gynaecologists. In 2004 hospi-
talizations due to female GWs totalled 512 plus 1728 day-
admissions. Including the cost of the speciﬁc medicines (approx.
€2.4 M/year for imiquimod), the overall cost to the Italian NHS
was estimated as €4.3 M per year for the diagnosis and treatment
of female GWs (approx. 9.2M € for the whole population). Using
data from Merito (ISPOR Dublin 2007) estimating the average
cost for outpatient management of GWs as €147/case, the total
expenditure for the management of the GWs in the Italian female
population could be up to €7.1 M. CONCLUSIONS: The NHS
expenditure for the management of GW in the Italian female
population was estimated to represent 2.1–4.4% of the total
expenditure for prevention and treatment of HPV-related cervical
cancer disease.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) and Hepatitis
B virus (HBV) are the two leading causes of liver disease in the
world. Approximately 2%-10% of HCV patients worldwide are
estimated to also have HBV, resulting in greater disease burden.
We analyze insurance claims to assess resource use and costs
among managed care enrollees with chronic HCV and HBV
co-infection compared to those with chronic HCV alone.
METHODS:AUS claims database spanning the period January 1,
2002 toDecember 31, 2006was retrospectively analyzed. Patients
were classiﬁed into 2 groups: 1) chronic HCV without HBV or
HIV (N = 27,296), and 2) chronic HCV and HBV co-infection
without HIV (N = 2,525). An index date was set as the date of
the ﬁrst observed chronic HCV diagnosis or date of diagnosis of
co-infection. Patients had continuous plan enrollment for 3
months pre- and 12 months post-index. Mean per patient use
and costs of all medical and pharmacy services were assessed over
12 months post-index. RESULTS: Patients with HCV alone had
61 encounters and total cost of $20,258 compared to 67 encoun-
ters and total cost of $23,494 for co-infected patients (P < 0.05).
Hospitalization rates were similar across the groups but, per
patient hospital costs were more than $2000 greater for
co-infected patients (P < 0.05). Co-infected patients stayed longer
in the hospital (9.2 vs. 7.6 days, P < 0.05) and also had higher
costs for laboratory services and other outpatient/ ancillary ser-
vices (both P < 0.05). There were no signiﬁcant differences in
encounters and costs related to physician ofﬁce and emergency
department visits. After controlling for demographics and comor-
bidities inmultivariate analyses, co-infected patients had 4.4more
encounters and incurred $1885 more in total costs compared
to those with HCV alone (P < 0.05). CONCLUSIONS: Chronic
HCV and HBV co-infection leads to signiﬁcantly greater con-
sumption of health care resources and imposes greater burden on
managed compared to chronic HCV alone.
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OBJECTIVES: We generate national estimates of inpatient costs,
length of stay (LOS), and probability of death among patients
infected with Hepatitis C Virus (HCV), human immunodeﬁ-
ciency virus (HIV), and those co-infected with both. METHODS:
Discharge data from the 2005 HCUP Nationwide Inpatient
Sample, the largest all-payer inpatient care database in the United
States (US) were analyzed. Hospitalizations were categorized into
mutually exclusive groups based on ICD-9-CM diagnosis codes:
HCV only, HIV only, HCV and HIV, and no HCV or HIV.
Weighted estimates of LOS, costs, and probability of death were
calculated for each stay. RESULTS: There were 390,975 hospi-
talizations for HCV, 136,596 for HIV, and 26,000 for HCV and
HIV co-infections. The average LOS for HCV-related hospital-
izations was 6.03 days. LOS for HIV-related hospitalizations was
higher at 7.87 days (P < 0.0001), similar to the LOS for hospi-
talizations pertaining to HCV and HIV co-infection (7.88 days).
In comparison, hospitalizations not related to HCV or HIV had
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an average LOS of only 4.62 days. The total cost per hospital-
ization was also lowest for HCV at $11,797 and was signiﬁcantly
higher for HIV ($14,595, P < 0.0001). The total cost per hospi-
talization for HIV and HCV co-infections was $14,686. The
total cost of non-HCV or HIV hospitalizations was nearly half
($8,859). The probability of death associated with HCV, HIV,
and co-infected HCV and HIV was 3.5%, 5.1% and 5.6%
respectively while the probability of death associated with non-
HIV or HIV-related hospitalizations was only 2.1%. CONCLU-
SIONS: This is one of few studies to quantify differences in
inpatient costs and outcomes associated with HCV, HIV, and
HCV and HIV co-infection in a multi-payer US population.
Hospitalizations related to HCV and HIV co-infections were
longer and more expensive compared to those related to HCV
only. Policy and other decision makers should be aware of this
burden as strategies to allocate resources are developed.
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OBJECTIVES: Central venous catheter (CVC) is the main reason
for intrahospitalary bacteraemia. The prevalence of nosocomial
Catheter-related bacteraemia (CRB) hospitalwide is 6.58%.
Gram-positive microorganisms are responsible for more than
50% of these bacteraemia. This study aimed to clear manage-
ment of non-permanent CRB caused by Gram-positives and
resource use associated. METHODS: A multicenter, observa-
tional, transversal cost study was carried out, where every proven
CRB was recorded. CRB was deﬁned as a positive culture from
the distal end of the catheter plus at least a positive peripheral
blood culture involving isolations of the same micro-organism-.
The study was performed from the hospital perspective; therefore
only medical direct costs (€2007) were included: hospitalization
cost, diagnosis test cost, and analytical cost. Costs were obtained
from Spanish databases. Qualitative and quantitative descriptive
analyses were made for all the variables. RESULTS: A total of 23
proven CRB and more than 400 suspected catheter infections,
which did not meet criteria inclusion, were identiﬁcated, in 5
Spanish hospitals. Average age was 60.17 (SD 13,799) years old,
being 52.2% women. Coagulase-negative Staphylococcus was
the micro-organism responsible for the 73.9% of CRB, mostly
S. epidermidis (56.5%). S. aureus was isolated in 17.4% cases.
Vancomycin was the most frequently prescribed antibiotic
(47.8%), followed by teicoplanin (26.1%), with a mean duration
of 8.48 (SD 4481) days. Nevertheless, 52% patients required
new antibiotics as cloxaciline (20%), vancomycin (20%) and
teicoplanin (20%), due to treatment failure, with a mean extra-
hospital treatment duration of 5.7 (SD 4547) days. Mean time
to CRB resolution-time since initial clinical signs until fever
clearance- was 6.65 (SD 4.608) days, with a mean cost per
episode of €4375.42. The 95% of costs are attributable to length
of hospitalization, with a mean cost per episode of €4150.81,
therefore, being the driver cost. CONCLUSIONS: CRB is asso-
ciated with a profound increase in resource use. Prevention, early
diagnosis, and intervention for non-permanent catheter related
bacteraemia might result in cost savings for the National Health
System.
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OBJECTIVES: Previous economic analyses of gram + cSSTIs
have not included costs related to outpatient parenteral antibiotic
therapy (OPAT). The objective of this analysis was to develop a
core model framework and appropriate inputs to estimate
medical and drug costs within both inpatient and outpatient
components of care for treating gram + cSSTIs and serve as a
basis for comparing vancomycin with newer antibiotics.
METHODS: A 4-week decision model was developed to estimate
the direct total, inpatient, and outpatient costs of treating
gram + cSSTIs from a payer perspective taking into account suc-
cesses, failures, and adverse events. Published literature provided
clinical inputs and resource use data, with validation by expert
opinion. Cost data was derived from literature and standard CPT
coding reimbursements. Sensitivity analyses tested efﬁcacy, com-
plication rates, length of stay, and other resource use parameters.
Costs were reported in 2008US$. RESULTS: Drug acquisition
cost for 14 days of vancomycin 1gm IV q12hr was $257;
however, the total 4-week cost of treatment including clinical
failures, complications, and OPAT ranged from $8,214–$13,133
(66–86% of cost inpatient, 14–33% outpatient). Important
vancomycin cost drivers beyond the inpatient stay ($1219/day)
included OPAT cost ($175/day), line placement and complica-
tions related to OPAT ($739/patient), physician visits ($192/
patient), injection supply/admin costs ($183/patient), and lab
work ($98/patient). Antibiotics with favorable dosing/admin-
istration proﬁles reduced OPAT costs and provided opportunity
for early discharge. The most sensitive model variables for total
cost were the MRSA efﬁcacy rate, length of hospital stay, days of
OPAT and line complications. CONCLUSIONS: The model
framework and results suggest that the costs associated with
generic vancomycin for treatment of cSSTIs may be substantial,
with a signiﬁcant portion of costs extending into the outpatient
arena. The budget impact of newer antimicrobials should be
evaluated in the context of total medical cost offsets from both
inpatient and outpatient perspectives.
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OBJECTIVES: To understand real-world impacts of venous leg
ulcer (VLU) on direct medical costs and productivity in the US
and the UK. METHODS: This prospective, observational, multi-
center study enrolled 112 patients with VLU (US: 76 and UK:
36). Patients were followed for 12 weeks or until all their ulcers
healed in 2007 and 2008. Data were gathered on health care
resources used at the study site as well as outside the study site
(using patient diaries). Standard national data sources were used
to assign unit costs to the resources used. The mean direct
medical cost was estimated from the US payer, US provider, and
UK National Health Service (NHS) perspectives separately and
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